Literature DB >> 33762378

Loperamide: an emerging drug of abuse and cause of prolonged QTc.

George Whittaker1, Joseph Newman2.   

Abstract

Loperamide is an over-the-counter medication which is commonly used to treat diarrhoea. In excessive doses, loperamide acts as an opioid on the central nervous system, which contributes to its increasing popularity as an alternative substance for opiate addictions. High doses for prolonged periods can cause prolonged QTc and provoke life-threatening arrhythmias, such as ventricular fibrillation. We report the case of a young female who developed dangerous arrhythmias as a result of chronic loperamide overdosing. Following syncopal episodes at rest, she was admitted for a period of monitored observation and later discharged with a plan to taper her loperamide in the community. Upon second presentation, her loperamide was replaced with buprenorphine patches, which were then weaned successfully in the community. Despite this, she passed away several months later, most likely from an underlying congenital cardiac arrhythmia which was unmasked by excessive use of loperamide. © Royal College of Physicians 2021. All rights reserved.

Entities:  

Keywords:  addiction; arrhythmias; loperamide; prolonged QTc

Mesh:

Substances:

Year:  2021        PMID: 33762378      PMCID: PMC8002798          DOI: 10.7861/clinmed.2020-1046

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  5 in total

1.  2018 ESC Guidelines for the diagnosis and management of syncope.

Authors:  Michele Brignole; Angel Moya; Frederik J de Lange; Jean-Claude Deharo; Perry M Elliott; Alessandra Fanciulli; Artur Fedorowski; Raffaello Furlan; Rose Anne Kenny; Alfonso Martín; Vincent Probst; Matthew J Reed; Ciara P Rice; Richard Sutton; Andrea Ungar; J Gert van Dijk
Journal:  Eur Heart J       Date:  2018-06-01       Impact factor: 29.983

2.  Loperamide Abuse Associated With Cardiac Dysrhythmia and Death.

Authors:  William Eggleston; Kenneth H Clark; Jeanna M Marraffa
Journal:  Ann Emerg Med       Date:  2016-04-29       Impact factor: 5.721

3.  Brugada Syndrome Associated With Adolescent Loperamide Abuse.

Authors:  Bryan Stefek; L Timothy Wolfe; Mark Cohen
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

4.  Loperamide abuse and cardiotoxicity.

Authors:  Nichole A Smith; Matthew Sehring; Jefferson Chambers
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-09-19

5.  Loperamide Induced Life Threatening Ventricular Arrhythmia.

Authors:  Ankit Upadhyay; Vijaykumar Bodar; Mohammad Malekzadegan; Sharanjit Singh; William Frumkin; Aditya Mangla; Kaushik Doshi
Journal:  Case Rep Cardiol       Date:  2016-07-28
  5 in total
  3 in total

Review 1.  Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.

Authors:  Edoardo Savarino; Fabiana Zingone; Brigida Barberio; Giovanni Marasco; Filiz Akyuz; Hale Akpinar; Oana Barboi; Giorgia Bodini; Serhat Bor; Giuseppe Chiarioni; Gheorghe Cristian; Maura Corsetti; Antonio Di Sabatino; Anca Mirela Dimitriu; Vasile Drug; Dan L Dumitrascu; Alexander C Ford; Goran Hauser; Radislav Nakov; Nisha Patel; Daniel Pohl; Cătălin Sfarti; Jordi Serra; Magnus Simrén; Alina Suciu; Jan Tack; Murat Toruner; Julian Walters; Cesare Cremon; Giovanni Barbara
Journal:  United European Gastroenterol J       Date:  2022-06-13       Impact factor: 6.866

Review 2.  Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.

Authors:  Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain
Journal:  Biomed Res Int       Date:  2022-06-28       Impact factor: 3.246

3.  Evaluation of Prescription Medication Sharing Among Adults in South Korea: A Cross-Sectional Survey.

Authors:  Seulki Song; Seungyeon Kim; Sangyoon Shin; Young Lee; Euni Lee
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.